ABOUT US
Blue Horse Medical was established in December 2020, focusing on the development and production of cell immunotherapy products with tumor infiltrating lymphocyte (TIL) therapy as the core. The founding team has been deeply involved in the TIL field for many years. The core members include TIL laboratories from MD Anderson Cancer Center and well-known TIL companies in the United States, with long-term experience in research and development, industrialization, and enterprise management
Products & R&D
Newsroom
Suzhou Lanma Medical Technology Co., Ltd. tumor treatment solution research and development project environmental impact assessment first public announcement
Project Overview: It is proposed to carry out pilot tumor treatment program R&D in the existing leased 2039.8 square meters laboratory, mainly to carry out R&D related to tumor infiltrating lymphocyte tumor therapy, extract and train tumor infiltrating lymphocytes, detect the activity, quantity, sterility and killing function of the trained tumor infiltrating lymphocytes, and get a mature, stable and unique tumor infiltrating lymphocyte training method, with an annual R&D scale of 100 human copies for human tumor infiltrating lymphocytes.
Suzhou Lanma Medical Technology Co., Ltd. tumor treatment solution research and development new project environmental impact assessment first public announcement
The proposed tumor treatment program research and development pilot in the existing leased 2039.8 square meters laboratory, mainly for tumor infiltrating lymphocyte tumor therapy related research and development, extraction, training tumor infiltrating lymphocytes, detection of trained tumor infiltrating lymphocyte viability, quantity, sterility and killing function, to get a mature, stable and unique tumor infiltrating lymphocyte training method, the annual research and development scale for human tumor infiltrating lymphocytes for 100 people.
[First] Lanma Medical received tens of millions of dollars in Pre-A round financing, adding another strong returnee team to the domestic TILs track
(hereinafter referred to as "Blue Horse Medical" or "Blue Horse"), a biologically innovative pharmaceutical company, has recently received a multi-million dollar Pre-A round of financing co-led by Boyuan Capital and IDG Capital and followed by Suzhou High-Tech Venture Capital. Pre-A round of financing. The company said that the funding will be used mainly for the process development of TILs for solid malignancies and IND filing of TILs for multiple solid tumor types.
Science and Technology Vision | Lanma Medical's first product LM103 Injection IIT is officially launched!
Recently, Landma Medical, an enterprise introduced by the Science and Technology Recruitment Center of High-tech Zone, ushered in an important milestone of the company's research work. The investigator-initiated clinical trial (IIT) conducted by the company has recently completed the enrollment of the first patient, marking the official launch of the company's first product, LM103 injection IIT.
